# Statera Biopharma (STAB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/STAB
## Company Profile
- Ticker: STAB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy
## Stock Data
- Close: 0.0001 USD
- Market cap: Not available USD
- Last updated: 2026-10-08
## Business Overview
### Immune Modulation Company
Statera Biopharma developed therapies intended to restore immune balance across autoimmune disease, inflammation, infection, oncology, and radiation injury. Its disclosed portfolio represents the company's historical 2022-stage development strategy.
### AIMS Multi-Receptor Platform
The AIMS platform was based on noroxymorphone analogs designed to modulate opioid-growth-factor and Toll-like receptor pathways. The goal was to influence both cellular and antibody-mediated immune responses.
### Toll-Like Receptor Programs
Statera also developed compounds intended to activate or inhibit multiple Toll-like receptors. These programs were designed for inflammatory disease, viral illness, cancer, and immune restoration.
### Entolimod Radiation Countermeasure
Entolimod is a Toll-like receptor 5 agonist historically developed as a medical radiation countermeasure and for oncology-related uses. Statera later pursued a transaction to transfer rights to this program.
## Why The Stock Is Moving

As of Oct 8, 2026, STAB was little changed and closed at $0.0001. No new same-company headline was identified in the current news window.

## Recent News
- 2023-03-15 12:00 EST — [Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs](https://biopharmsignal.com/news/STAB/statera-biopharma-signs-letter-of-intent-for-merger-with-worksite-labs-099c61d6) — Source: Statera Biopharma
- 2022-06-14 11:30 EST — [Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm](https://biopharmsignal.com/news/STAB/statera-biopharma-announces-bf-borgers-cpa-pc-as-independent-registered-public-a-71c54feb) — Source: Statera Biopharma
- 2022-05-23 20:05 EST — [Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing](https://biopharmsignal.com/news/STAB/statera-biopharma-receives-notification-letter-from-nasdaq-regarding-form-10-q-f-935c1f18) — Source: Statera Biopharma
- 2022-05-13 11:30 EST — [Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products](https://biopharmsignal.com/news/STAB/statera-biopharma-and-lay-sciences-inc-announce-intent-to-enter-strategic-partne-5e43679a) — Source: Statera Biopharma
- 2022-04-27 20:10 EST — [Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone](https://biopharmsignal.com/news/STAB/statera-biopharma-and-immune-therapeutics-inc-announce-strategic-agreement-for-r-317e2285) — Source: Statera Biopharma